Anu Chittenden

Anu Chittenden

Auto-generated profile, based on publicly available information

Anu Chittenden

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
RHRachel Hodan
Rachel Hodan
LRLinda Rodgers-Fouche
Linda Rodgers-Fouche
ACAnu Chittenden
Anu Chittenden
MDMev Dominguez-Valentin
Mev Dominguez-Valentin
JFJames Ferriss
James Ferriss
OCOn behalf of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer
On behalf of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer

1 February 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
LBLeah H. Biller
Leah H. Biller
KMKate Mittendorf
Kate Mittendorf
MHMiki Horiguchi
Miki Horiguchi
ACAlyson Caruso
Alyson Caruso
ACAnu Chittenden
Anu Chittenden
MYMatthew B. Yurgelun
Matthew B. Yurgelun
PURPOSE: Clinical risk assessment models can identify patients with hereditary cancer susceptibility, but it is unknown how multigene cancer syndrome prediction models compare with syndrome-specific models in assessing risk for individual syndromes such as Lynch syndrome (LS). Our aim was to compare PREMMplus (a 19-gene cancer risk prediction model) with PREMM5 (a LS gene–specific model) for LS identification. METHODS: We analyzed data from two cohorts of patients undergoing germline testing from a commercial laboratory (n = 12,020) and genetics clinic (n = 6,232) with personal and/or family histories of LS-associated cancer. Individual PREMMplus and PREMM5 scores were calculated for all patients. Using a score cutoff of ≥ 2.5%, we calculated the sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for identifying LS with each model. Overall ability to discriminate LS carriers from noncarriers was measured using receiver operating characteristic (ROC)-AUC. RESULTS: PREMMplus had higher sensitivity than PREMM5 in the laboratory- (89.2% [95% CI, 84.4 to 93.0] v 63.7% [95% CI, 57.0 to 70.0]) and clinic-based cohorts (90.5% [95% CI, 84.8 to 94.6] v 60.8% [95% CI, 52.7 to 68.4]). NPV was ≥98.8% for both models in both cohorts. PREMM5 had superior discriminatory capacity to PREMMplus in the laboratory- (ROC-AUC, 0.81 [95% CI, 0.77 to 0.84] v 0.71 [95% CI, 0.67 to 0.75]) and clinic-based cohorts (ROC-AUC, 0.79 [95% CI, 0.75 to 0.84] v 0.68 [95% CI, 0.64 to 0.73]). CONCLUSION: Both PREMM5 and PREMMplus demonstrated high NPVs (>98%) in LS discrimination across all patient cohorts, and both models may be used to identify individuals at risk of LS. The choice of which model to use can be based on the goals of risk assessment and patient population.

7 May 2026 in JCO Oncology Practice
Verified
Journal Article
Open access
JSJill E. Stopfer
Jill E. Stopfer
MHMiki Horiguchi
Miki Horiguchi
ACAnu Chittenden
Anu Chittenden
CTCarmen G. Tso
Carmen G. Tso
SCSophie R. Cahill
Sophie R. Cahill
HRHuma Rana
Huma Rana
PURPOSE: Germline genetic testing is critical for guiding cancer treatment, identifying hereditary syndromes, and enabling cascade testing for at-risk relatives. However, barriers such as limited access to genetic counselors and long wait times may hinder its implementation. This study evaluates the Rapid Access Cancer Genetic Testing Program ( Rapid ), a streamlined workflow incorporating a pretest video education (VE) process navigation by genetic testing coordinators (GTCs), and targeted involvement of genetic counselors and physicians for patients with pathogenic or likely pathogenic (P/LP) results. METHODS: A retrospective review of 2,767 oncology patients who participated in Rapid between May 2021 and May 2023 was conducted. Eligible patients had breast, prostate, pancreatic, ovarian, or colorectal cancer and met National Comprehensive Cancer Network testing guidelines. Rapid visits included VE, pedigree collection, consenting, and genetic testing coordination by GTCs. Patients with P/LP results were seen for follow-up by genetic counselors and cancer genetics physicians. RESULTS: Of the 2,767 patients, 89.1% consented to genetic testing, and 87.9% completed testing. Among those tested, 13.2% had P/LP variants, with those in BRCA2, BRCA1, and CHEK2 being the most frequently identified. Disparities in testing completion were observed, with older age (≥50 years), Black or African American race, and pancreatic cancer diagnosis associated with lower odds of testing. Pancreatic and prostate cancer diagnoses, as well as recessive genetic findings, were associated with lower follow-up rates. CONCLUSION: Rapid demonstrated high genetic testing uptake and effective integration into oncology workflows, enabling timely treatment decisions. Although the program optimized resource use and reduced barriers, disparities in testing remain. Future efforts should address these inequities and evaluate the long-term impact of genetic testing on patient outcomes.

13 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
Giulia OngaroGiulia Ongaro
Giulia Ongaro
CSCaroline Salafia
Caroline Salafia
RSRania Sheikh
Rania Sheikh
ESElizabeth Schofield
Elizabeth Schofield
DCDana Farengo Clark
Dana Farengo Clark
JHJada G. Hamilton
Jada G. Hamilton
Purpose: Female BRCA1/2 carriers face high breast cancer risks and complex preventive decisions, which can generate decisional conflict. Polygenic Risk Scores (PRS) offer individualized risk estimates that may support decision-making. We examine whether PRS disclosure reduces decisional conflict in BRCA1/2 carriers and whether PRS magnitude interacts with numeracy and tolerance for ambiguity. Methods: Unaffected BRCA1/2 carriers ( N= 354) were assessed pre PRS disclosure (T0), one-week (T1), and six-months post-disclosure (T2). PRS were translated into 10-year and lifetime absolute breast cancer risk estimates. Mixed-effects models tested changes in decisional conflict, and regression/moderation analyses tested PRS effects and interactions with numeracy and tolerance for ambiguity. Results: Decisional conflict decreased significantly after PRS disclosure. Higher 10-year risk was associated with greater decisional conflict immediately after disclosure. Lifetime risk alone did not predict conflict. Tolerance for ambiguity moderated the effect of lifetime risk at T1: women with low/average tolerance experienced higher conflict with high PRS and lower conflict with low PRS. Numeracy, age, and family cancer history did not moderate PRS effects. Conclusion: Decisional conflict decreased post-PRS disclosure, with short-term responses influenced by tolerance for ambiguity. Findings suggest that PRS can complement standard BRCA1/2 genetic counseling and highlight the need for tailored risk communication.

21 May 2026 in Genetics in Medicine
Verified
Journal Article
Open access
Giulia OngaroGiulia Ongaro
Giulia Ongaro
CSCaroline Salafia
Caroline Salafia
RSRania Sheikh
Rania Sheikh
ESElizabeth Schofield
Elizabeth Schofield
DCDana Farengo Clark
Dana Farengo Clark
JHJada G. Hamilton
Jada G. Hamilton
Women with BRCA1/2 pathogenic variants (PVs) face high breast cancer risks and complex preventive decisions, including whether to undergo risk-reducing mastectomy, which can generate decisional conflict. Polygenic Risk Scores (PRS) offer individualized risk estimates that may support informed preventive decisions. We examine whether PRS disclosure reduces decisional conflict about risk-reducing mastectomy in women with BRCA1/2 PVs and whether PRS magnitude interacts with individual characteristics. Unaffected women with BRCA1/2 PVs (N=354) were assessed pre PRS disclosure (T0), one-week (T1), and six-months post-disclosure (T2). PRS were translated into 10-year and lifetime absolute breast cancer risk estimates. Mixed-effects models tested changes in decisional conflict, and generalized regression analyses tested PRS effects and interactions with individual characteristics RESULTS: Decisional conflict decreased significantly after PRS disclosure. Higher 10-year risk was associated with greater decisional conflict immediately after disclosure. Lifetime risk alone did not predict conflict. Tolerance for ambiguity moderated the effect of lifetime risk at T1: women with lower or medium tolerance experienced higher conflict with high PRS and lower conflict with low PRS. Numeracy, age, and family cancer history did not moderate PRS effects. Decisional conflict decreased post-PRS disclosure, with short-term responses varying by tolerance for ambiguity, highlighting the importance of tailoring risk communication to patients' psychological characteristics.